CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Subscribe To Our Newsletter & Stay Updated